Literature DB >> 23913094

A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results.

Di Cui1, Feng Sun, Jian Zhuo, Xiaowen Sun, Bangmin Han, Fujun Zhao, Yifeng Jing, Jun Lu, Shujie Xia.   

Abstract

OBJECTIVE: To report the results of a randomized prospective trial with a 4-year follow-up, comparing the thulium laser resection of the prostate-tangerine technique (TmLRP-TT) with transurethral resection of prostate (TURP) for treatment of symptomatic benign prostatic hyperplasia (BPH).
METHODS: BPH patients (96) were randomized for surgical treatment with TmLRP-TT (47) or TURP (49). All patients were assessed pre-operatively and followed at 12, 24, 36, and 48 months post-operatively. Several parameters related to BPH were collected at each follow-up, including International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urinary flow rates (Qmax), and post-void residual volume (PVR). All late complications were also recorded.
RESULTS: Dramatic improvement in micturition parameters was observed after TmLRP-TT compared with pre-operative values. Median IPSS decreased 75.6 % in the subsequent 12 months and 61.2 % in 48 months, while median QoL decreased by 80.4 and 59.1 %, respectively. Compared with baseline, numerical values of Qmax increased 1.07-fold and those of PVR decreased 73.1 % in the fourth year. Moreover, all micturition parameters in the TmLRP-TT group were similar to those of TURP patients at every annual assessment. Some late complications after the operations were also observed: one patient suffered from urethral strictures and one from bladder-neck contractures after TmLRP-TT. Re-operation rates were equal in the two groups.
CONCLUSIONS: Micturition remained stable after TmLRP-TT during the 4-year follow-up. Outcomes compared favourably with TURP, with lower peri-operative morbidity and equally low occurrence of late adverse effects. Thus, TmLRP-TT can be an available option for BPH patients, especially older, high-risk patients.

Entities:  

Mesh:

Year:  2013        PMID: 23913094     DOI: 10.1007/s00345-013-1103-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  31 in total

Review 1.  EAU guidelines on laser technologies.

Authors:  Thomas R W Herrmann; Evangelos N Liatsikos; Udo Nagele; Olivier Traxer; Axel S Merseburger
Journal:  Eur Urol       Date:  2012-01-17       Impact factor: 20.096

2.  Two-micron (thulium) laser resection of the prostate-tangerine technique: a new method for BPH treatment.

Authors:  Shu-Jie Xia
Journal:  Asian J Androl       Date:  2009-04-27       Impact factor: 3.285

3.  Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years.

Authors:  Peter J Gilling; Liam C Wilson; Colleen J King; Andre M Westenberg; Christopher M Frampton; Mark R Fraundorfer
Journal:  BJU Int       Date:  2011-08-23       Impact factor: 5.588

4.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

Review 5.  Thulium: YAG 2 mum cw laser prostatectomy: where do we stand?

Authors:  T Bach; S J Xia; Y Yang; S Mattioli; G M Watson; A J Gross; T R W Herrmann
Journal:  World J Urol       Date:  2010-03-05       Impact factor: 4.226

Review 6.  Therapeutic applications of lasers in urology: an update.

Authors:  Nathaniel M Fried
Journal:  Expert Rev Med Devices       Date:  2006-01       Impact factor: 3.166

7.  Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study.

Authors:  Robin Ruszat; Stephen F Wyler; Michael Seitz; Kurt Lehmann; Constanze Abe; Gernot Bonkat; Oliver Reich; Thomas C Gasser; Alexander Bachmann
Journal:  BJU Int       Date:  2008-07-29       Impact factor: 5.588

8.  A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams).

Authors:  A H H Tan; P J Gilling; K M Kennett; C Frampton; A M Westenberg; M R Fraundorfer
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

9.  [Comparison of holmium and thulium laser in transurethral enucleation of the prostate].

Authors:  Qiang Shao; Feng-Bo Zhang; Dong-Hao Shang; Ye Tian
Journal:  Zhonghua Nan Ke Xue       Date:  2009-04

10.  Endoscopic vaporesection of the prostate using the continuous-wave 2-microm thulium laser: outcome and demonstration of the surgical technique.

Authors:  Roman Szlauer; Robert Götschl; Aria Razmaria; Ljiljana Paras; Nikolaus T Schmeller
Journal:  Eur Urol       Date:  2008-11-12       Impact factor: 20.096

View more
  17 in total

1.  Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis.

Authors:  Zheng Deng; Menghao Sun; Yiping Zhu; Jian Zhuo; Fujun Zhao; Shujie Xia; Bangmin Han; Thomas R W Herrmann
Journal:  World J Urol       Date:  2018-04-12       Impact factor: 4.226

2.  Update on lasers in urology 2015.

Authors:  Thomas R W Herrmann; Thorsten Bach
Journal:  World J Urol       Date:  2015-04       Impact factor: 4.226

Review 3.  Nomenclature in thulium laser treatment of benign prostatic hyperplasia: it's time to pull the rabbit out of the hat.

Authors:  Serena Maruccia; Irene Fulgheri; Emanuele Montanari; Stefano Casellato; Luca Boeri
Journal:  Lasers Med Sci       Date:  2021-01-03       Impact factor: 3.161

Review 4.  Evidence of the efficacy and safety of the thulium laser in the treatment of men with benign prostatic obstruction.

Authors:  Yana Barbalat; Marissa C Velez; Christopher I Sayegh; Doreen E Chung
Journal:  Ther Adv Urol       Date:  2016-02-24

5.  The efficacy and safety of 2-μm continuous laser in the treatment of high-risk patients with benign prostatic hyperplasia.

Authors:  Wei Tao; Chuanyang Sun; Boxin Xue; Dongrong Yang; Mingchao Wang; Chunjie Cai; Yuxi Shan
Journal:  Lasers Med Sci       Date:  2016-12-13       Impact factor: 3.161

Review 6.  Thulium laser versus standard transurethral resection of the prostate for benign prostatic obstruction: a systematic review and meta-analysis.

Authors:  Yiping Zhu; Jian Zhuo; Dongliang Xu; Shujie Xia; Thomas R W Herrmann
Journal:  World J Urol       Date:  2014-10-09       Impact factor: 4.226

7.  [Long-term outcome after endoscopic enucleation of the prostate : From monopolar enucleation to HoLEP and from HoLEP to EEP].

Authors:  T R W Herrmann
Journal:  Urologe A       Date:  2016-11       Impact factor: 0.639

8.  The effectiveness and safety of three surgical procedures for the treatment for benign prostatic hyperplasia: A network meta-analysis.

Authors:  Jiusong Yan; Liang Gao; Guangyong Xu; Junyong Zhang
Journal:  Heliyon       Date:  2022-10-04

9.  Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers.

Authors:  Feng Sun; Bangmin Han; Di Cui; Fujun Zhao; Xiaowen Sun; Jian Zhuo; Yifeng Jing; Haitao Liu; Shujie Xia; Yong Yang; Guangheng Luo; Fengfu Guo
Journal:  World J Urol       Date:  2014-12-09       Impact factor: 4.226

10.  Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT.

Authors:  Jo Worthington; J Athene Lane; Hilary Taylor; Grace Young; Sian M Noble; Paul Abrams; Aideen Ahern; Sara T Brookes; Nikki Cotterill; Lyndsey Johnson; Rafiyah Khan; Aida Moure Fernandez; Tobias Page; Satchi Swami; Hashim Hashim
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.